WASHINGTON -- Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), ...
One of the better stocks on the New York Stock Exchange (NYSE) this morning is ADT Inc (NYSE:ADT), up 3.8% to trade at $6.51. This is after the home security specialist said it's selling its Canadian ...
Safety results were reported descriptively for the NUBEQA plus ADT arm only, as safety data were not routinely collected in the CHAARTED ADT-alone arm. In the NUBEQA plus ADT matched population, 58% ...
Adding 6 months of androgen deprivation therapy (ADT) to dose-escalated radiation therapy (RT) does not provide a survival advantage to patients with intermediate-risk prostate cancer, but it does ...
Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer. Adding a longer course of androgen ...
Impact of cabazitaxel on metastatic bone health in patients with castration resistant prostate cancer previously treated with docetaxel: CaBone Study. Background: Androgen deprivation therapy (ADT) by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results